THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
Main Article Content
Keywords
Myeloproliferative neoplasms, tyrosine kinase inhibitor, Chronic Myeloid Leukemia, Jak2 inhibitors
Abstract
The concomitant presence of BCR-Abl1 and JAK2/CALR mutations in Myeloproliferative neoplasms (MPNs) is rare. The clinical presentation of Chronic Myelogenous Leukemia (CML) and Ph-negative MPN may vary, but CML seems to play a dominant role, so patients usually receive treatment with tyrosine kinase inhibitor (TKI) only. The second Ph-negative MPN becomes evident under the selective pressure of the TK.I.
Downloads
Abstract 48
PDF Downloads 37
HTML Downloads 2
References
2. Zanelli M., Bisagni A., Sanguedolce F. et al.(2023) Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. Front oncol.; 13: 01-14.
3. Soderquist CR, Ewalt MD, Czuchlewski DR, et al. (2018) Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology 31(5):690–704.
4. Martin-Cabrera P, Haferlach C, Kern W, et al. (2014) BCR-ABL1-positive and JAK2 V617F-positive clone in 23 patients with both aberrations reveal biologic and clinical importance. BJH (2017) 176:131–43.
5. Iurdo A., Gianelli U., Rapezzi D et al. (2014) Imatinib and Roxilitinib association: first experience in two patients. Haematologica: 99: e76-77
6. Zhou A, Knoche EM, Engle EK, Fisher DAC and Oh ST (2015) Concomitant JAK2V617F positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5:e351.
7. Pieri L, Spolverini A, Scappini B, et al. (2011) Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood 118(12):3445–6.
8. Verstovsek S, Mesa RA, Gotlib J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med.; 366: 799-807.
9. Bader G. and Dreiling B. (2019) Concurrent Jak2-Positive Myeloproliferative disorder and Chronic myelogenous leukaemia: a novel entity? A case report with review of the literature. Journal of Investigative medicine:vol 7: 1-5.
10. Kandarpa M, Wu YM, Robinson D et al. (2017) Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. AJH 92:555–61.
11. Boddu P, Chihara D, Masarova L. , Pemmaraju N., Patel KP and Verstovsek S. (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol;97 (11):2071-2080.
12. Zhao Y, Reddi D, McCracken J, et al. (2022) Sequential development of JAK2V617F mutation and BCR-ABL1 fusion in individual patients with myeloproliferative neoplasms. A linear clonal evolution or parallel clonal competition? Arch Pathol Lab Med 146:710–7.
13. Zhang Y, Bi H, Wang Y, Chen L, et al. (2022) BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. Blood Sci 4:199–204.
14. Sorà F, Chiusolo P, Autore F, et al. (2021) Is allogenic transplantation an option in patients affected by concurrent myelofibrosis and chronic myeloid leukemia (CML)? Mediterr J Hematol Infect Dis 13(1): e2021062.
15. Ryu J, Chu D, Park B, et al. (2022) Rare case of accelerated-phase chronic myeloid leukemia diagnosed during treatment for JAK2 V617F-positive primary myelofibrosis. Lab Med 53:e140–4.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.